<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2303">
  <stage>Registered</stage>
  <submitdate>25/03/2009</submitdate>
  <approvaldate>25/03/2009</approvaldate>
  <nctid>NCT00869817</nctid>
  <trial_identification>
    <studytitle>Dominantly Inherited Alzheimer Network (DIAN)</studytitle>
    <scientifictitle>Dominantly Inherited Alzheimer Network (DIAN)</scientifictitle>
    <utrn />
    <trialacronym>DIAN</trialacronym>
    <secondaryid>U19AG032438</secondaryid>
    <secondaryid>IA0147</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - Mutation Positive

2 - Mutation Negative

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Positive predictive power of a biomarker or group of biomarkers</outcome>
      <timepoint>Variable follow-up assessment based on age in relation to age at onset of affected parent.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging</outcome>
      <timepoint>Variable follow-up assessment based on age in relation to age at onset of affected parent</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinical markers also examined from clinical interview and cognitive testing</outcome>
      <timepoint>Variable follow-up assessment based on age in relation to age at onset of affected parent</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent obtained from participant and collateral source prior to any
             study-related procedures.

          -  Aged 18 (inclusive) or older and the child of an affected individual (clinically or by
             testing) in a pedigree with a known mutation for ADAD.

          -  Cognitively normal. Primary enrollment will focus on recruitment of asymptomatic adult
             children who are more than 15 years younger than the estimated age of symptom onset.
             Enrollment of new participants with very mild, mild, or moderate cognitive impairment
             is allowed with the prior approval of the DIAN Coordinating Center.

          -  Has two persons who are not their full-blooded siblings who can serve as collateral
             sources for the study.

          -  Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade
             level (international equivalent) or above.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Under age 18

          -  Medical or psychiatric illness that would interfere in completing initial and
             follow-up visits

          -  Requires nursing home level care

          -  Has no one who can serve as a study informant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Neuroscience Research Australia - Sydney</hospital>
    <hospital>Mental Health Research Institute, University of Melbourne - Melbourne</hospital>
    <hospital>Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University - Perth</hospital>
    <postcode>2031 - Sydney</postcode>
    <postcode>3130 - Melbourne</postcode>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>TÃ¼bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Washington University School of Medicine</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute on Aging (NIA)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to identify potential biomarkers that may predict the
      development of Alzheimer's disease in people who carry an Alzheimer's mutation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00869817</trialwebsite>
    <publication>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446-52.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.
Godbolt AK, Cipolotti L, Anderson VM, Archer H, Janssen JC, Price S, Rossor MN, Fox NC. A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase. 2005 Feb;11(1):56-64.
Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991 Apr;41(4):469-78.
Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005 May;62(5):758-65.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Randall J. Bateman, MD</name>
      <address>Washington University School of Medicine</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>DIAN Global Coordinator</name>
      <address />
      <phone>314-747-1940</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>